SLC1A2

solute carrier family 1 member 2, the group of Solute carrier family 1

Basic information

Region (hg38): 11:35251205-35420063

Links

ENSG00000110436NCBI:6506OMIM:600300HGNC:10940Uniprot:P43004AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • undetermined early-onset epileptic encephalopathy (Supportive), mode of inheritance: AD
  • developmental and epileptic encephalopathy, 41 (Moderate), mode of inheritance: AR
  • developmental and epileptic encephalopathy, 41 (Strong), mode of inheritance: AD
  • developmental and epileptic encephalopathy, 41 (Limited), mode of inheritance: AR
  • developmental and epileptic encephalopathy, 41 (Definitive), mode of inheritance: AD

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Developmental and epileptic encephalopathy 41ADGeneralGenetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testingNeurologic23934111; 27476654

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the SLC1A2 gene.

  • Developmental and epileptic encephalopathy, 41 (1 variants)
  • not provided (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the SLC1A2 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
2
clinvar
92
clinvar
17
clinvar
111
missense
1
clinvar
6
clinvar
142
clinvar
34
clinvar
24
clinvar
207
nonsense
1
clinvar
1
start loss
2
clinvar
2
frameshift
1
clinvar
3
clinvar
4
inframe indel
2
clinvar
2
splice donor/acceptor (+/-2bp)
4
clinvar
4
splice region
5
13
4
22
non coding
2
clinvar
43
clinvar
10
clinvar
55
Total 1 7 156 171 51

Variants in SLC1A2

This is a list of pathogenic ClinVar variants found in the SLC1A2 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
11-35260895-T-A Uncertain significance (Nov 30, 2023)3364691
11-35260900-C-T Likely benign (Jul 13, 2023)2919841
11-35260903-A-G Likely benign (May 22, 2022)2179652
11-35260904-C-T Developmental and epileptic encephalopathy, 41 Uncertain significance (Aug 04, 2023)2157513
11-35260905-G-A Likely benign (Dec 09, 2023)1439675
11-35260910-C-G Uncertain significance (Nov 01, 2022)1307851
11-35260912-A-T Likely benign (Sep 12, 2022)2094842
11-35260918-T-C Likely benign (Mar 12, 2022)2153348
11-35260920-C-T Uncertain significance (Apr 22, 2022)2129360
11-35260921-C-T SLC1A2-related disorder Benign (Jan 28, 2024)771955
11-35260925-A-G Benign (Jul 25, 2023)2077762
11-35260926-C-T Uncertain significance (Oct 21, 2022)1916692
11-35260932-A-T Inborn genetic diseases Uncertain significance (Jan 11, 2024)1362190
11-35260935-C-T Developmental and epileptic encephalopathy, 41 Conflicting classifications of pathogenicity (Oct 25, 2024)2144833
11-35260936-G-A Likely benign (Nov 10, 2023)2021547
11-35260939-T-C Likely benign (Jan 17, 2024)2200780
11-35260941-A-G Uncertain significance (Jan 26, 2022)2089684
11-35260948-A-G Likely benign (Aug 09, 2022)1564523
11-35260949-T-C Likely benign (Jan 03, 2024)1640771
11-35260960-A-C Likely benign (Dec 03, 2022)1094063
11-35260963-T-C Likely benign (Jul 29, 2022)1637788
11-35260983-C-T Likely benign (Sep 05, 2022)1945400
11-35265503-G-A Likely benign (May 01, 2022)2641721
11-35265511-T-C Likely benign (Mar 17, 2022)2113309
11-35265518-G-A Likely benign (Sep 16, 2022)2037671

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
SLC1A2protein_codingprotein_codingENST00000278379 11168858
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.7100.290125739061257450.0000239
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense2.282173350.6490.00001793756
Missense in Polyphen55144.970.379391632
Synonymous-0.2861351311.030.000007711181
Loss of Function3.51421.60.1850.00000113259

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.000.00
Ashkenazi Jewish0.000.00
East Asian0.000.00
Finnish0.00004630.0000462
European (Non-Finnish)0.00003520.0000352
Middle Eastern0.000.00
South Asian0.00003270.0000327
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Sodium-dependent, high-affinity amino acid transporter that mediates the uptake of L-glutamate and also L-aspartate and D-aspartate (PubMed:7521911, PubMed:14506254, PubMed:15265858, PubMed:26690923). Functions as a symporter that transports one amino acid molecule together with two or three Na(+) ions and one proton, in parallel with the counter-transport of one K(+) ion (PubMed:14506254). Mediates Cl(-) flux that is not coupled to amino acid transport; this avoids the accumulation of negative charges due to aspartate and Na(+) symport (PubMed:14506254). Essential for the rapid removal of released glutamate from the synaptic cleft, and for terminating the postsynaptic action of glutamate (By similarity). {ECO:0000250|UniProtKB:P43006, ECO:0000269|PubMed:15265858, ECO:0000269|PubMed:26690923, ECO:0000269|PubMed:7521911}.;
Disease
DISEASE: Epileptic encephalopathy, early infantile, 41 (EIEE41) [MIM:617105]: A form of epileptic encephalopathy, a heterogeneous group of severe childhood onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. EIEE41 inheritance is autosomal dominant. {ECO:0000269|PubMed:27476654, ECO:0000269|PubMed:28777935}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Glutamatergic synapse - Homo sapiens (human);Amyotrophic lateral sclerosis (ALS) - Homo sapiens (human);Astrocytic Glutamate-Glutamine Uptake And Metabolism;Purine metabolism;Amino acid and oligopeptide SLC transporters;Transport of inorganic cations/anions and amino acids/oligopeptides;SLC-mediated transmembrane transport;Transport of small molecules;Neuronal System;Histidine metabolism;Glutamate Neurotransmitter Release Cycle;Neurotransmitter release cycle;Neurotransmitter uptake and metabolism In glial cells;Transmission across Chemical Synapses (Consensus)

Recessive Scores

pRec
0.385

Intolerance Scores

loftool
0.145
rvis_EVS
-1.29
rvis_percentile_EVS
5.03

Haploinsufficiency Scores

pHI
0.570
hipred
Y
hipred_score
0.715
ghis
0.607

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.720

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Slc1a2
Phenotype
homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype; normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan);

Zebrafish Information Network

Gene name
slc1a2b
Affected structure
ON-bipolar cell
Phenotype tag
abnormal
Phenotype quality
functionality

Gene ontology

Biological process
ion transport;chemical synaptic transmission;visual behavior;response to wounding;multicellular organism aging;glutamate secretion;L-glutamate transmembrane transport;telencephalon development;adult behavior;cellular response to extracellular stimulus;multicellular organism growth;response to amino acid;positive regulation of glucose import;protein homotrimerization;D-aspartate import across plasma membrane;L-glutamate import across plasma membrane;neurotransmitter reuptake
Cellular component
plasma membrane;integral component of plasma membrane;cell surface;membrane;axolemma;glutamatergic synapse;integral component of presynaptic membrane
Molecular function
L-glutamate transmembrane transporter activity;high-affinity glutamate transmembrane transporter activity;protein binding;amino acid transmembrane transporter activity;glutamate:sodium symporter activity;metal ion binding